Pharmaceutical and healthcare market research company Manhattan Research releases its latest consumer marketing research module, "Online Adherence Programs: Evaluating Manufacturers' Opportunity to Impact Patient Adherence", as part of its Cybercitizen Health™ market research and strategic advisory service.

Researchers in the UK have found evidence that smoking cannabis can damage human DNA in ways that could potentially increase the risk of developing cancer. The findings, published in the journal Chemical Research in Toxicology, are an outcome of the ECNIS (Environmental cancer risk, nutrition and individual susceptibility) Network of Excellence, funded with EUR 11 million under the 'Food Quality and Safety' Thematic area of the Sixth Framework Programme (FP6) to study how diet and hereditary factors can influence environmental cancer risk.

Scientists in the UK and Switzerland have identified a signalling pathway, PI3K (phosphoinositide 3-kinase) that shows promise as a target for treating aggressive skin cancer. Their results, based on a study of the see-through zebrafish, are published in the journal Disease Models and Mechanisms.

CAST PHARMA, a premier European 3D pharmaceutical and biomedical animation production company, is pleased to announce the availability of an advanced Demo-DVD to make its audiovisual material more widely available to the existing and further customers from the biomedical and pharmaceutical domains.

Results from the Rheumatoid Arthritis: Insights, Strategies & Expectations (RAISE) survey of more than 500 rheumatoid arthritis (RA) patients throughout Europe and Canada revealed a majority of patients still suffer from pain (79 percent), fatigue (67 percent) and joint stiffness (57 percent) on a regular basis despite current treatment, while more than half (51 percent) of RA patients feel their disease controls their life.

First DataBank Europe (FDBE) is pleased to announce, in association with The Guild of Healthcare Pharmacists (GHP) and the UK Clinical Pharmacy Association (UKCPA), the 2010 FDBE/GHP/UKCPA Information Technology Award.

Can an aspirin a day keep the doctor away? New research, part of the EU-funded BIOMED (Biomedicine and health) programme, shows it can't all the time. The researchers have discovered that although regular use of aspirin can reduce the rate of non-fatal heart attacks or stroke by around 12%, there is a 33% increase in the risk of internal bleeding in people with no history of relevant disease (primary prevention). The findings are published in The Lancet journal.